Table 6.
T-cell Response to COVID-19 Vaccination in Patients With CLL
| Author | CLL N | T-cell Response (n Evaluable) | ||
|---|---|---|---|---|
| Seropositive | Seronegative | Correlation | ||
| Sun et al (2021)35 | 58 | 52.4% (21)a | 42.9% (21)a | P = 0.4b |
| Itchaki et al (2021)46 | 68 | 32% (68) | 68% (68) | P = 0.048b |
| Haydu et al (2022)41 | 36 | NA | 78% (9) | NA |
| Shen et al (2022)27 | 160 | 81% (25)c | 19% (6)d | NA |
aData missing for 1 patient.
bP value for correlation of T-cell response with antibody response.
cPatients with a normal response, albeit of variable intensity.
dPatients with a weak or negative response.
CLL = chronic lymphocytic leukemia; COVID-19 = coronavirus disease 2019; n = number of patients; NA = not available.